Clinical Applications of Liquid Biopsy in Non-Small Cell Lung Cancer Patients: Current Status and Recent Advances in Clinical Practice

被引：5
作者：
Park, Shinhee [1 ]
Lee, Jae-Cheol [2 ]
Choi, Chang-Min [2 ,3 ]
机构：
[1] Soonchunhyang Univ, Bucheon Hosp, Dept Internal Med, Div Allergy & Resp Med, Bucheon 14584, South Korea
[2] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul 05505, South Korea
[3] Univ Ulsan, Coll tMed, Asan Med Ctr, Dept Pulm & Crit Care Med, Seoul 05505, South Korea
来源：
JOURNAL OF CLINICAL MEDICINE | 2021年 / 10卷 / 11期
关键词：
lung cancer; liquid biopsy; non-small cell lung carcinoma; CIRCULATING TUMOR DNA; FREE NUCLEIC-ACIDS; RESISTANCE MUTATIONS; ACQUIRED-RESISTANCE; KRAS MUTATIONS; BLOOD-PLASMA; NSCLC; CRIZOTINIB; GEFITINIB; SERUM;
D O I：
10.3390/jcm10112236
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Recent advances in targeted and immune therapies have enabled tailored treatment strategies for advanced lung cancer. Identifying and understanding the genomic alterations that arise in the course of tumor evolution has become hugely valuable, but tissue biopsies are often insufficient for representing the whole cancer genome due to tumor heterogeneity. A liquid biopsy refers to the isolation and analysis of any tumor-derived material in the blood, and recent studies of this material have mostly focused on cell-free tumor DNA (ctDNA) in plasma. Indeed, liquid biopsy analysis is now expected to expand in utility and scope in clinical practice. In this review, we assess the biology and technical aspects of ctDNA analysis and discuss how it is currently applied in the clinic. Key points: Liquid biopsy is a potentially powerful tool in the era of personalized medicine for guiding targeted therapies in non-small cell lung cancer.
引用
收藏
页数：11
相关论文
共 77 条
  • [51] Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
    Paik, Paul K.
    Felip, Enriqueta
    Veillon, Remi
    Sakai, Hiroshi
    Cortot, Alexis B.
    Garassino, Marina C.
    Mazieres, Julien
    Viteri, Santiago
    Senellart, Helene
    Van Meerbeeck, Jan
    Raskin, Jo
    Reinmuth, Niels
    Conte, Pierfranco
    Kowalski, Dariusz
    Cho, Byoung Chul
    Patel, Jyoti D.
    Horn, Leora
    Griesinger, Frank
    Han, Ji-Youn
    Kim, Young-Chul
    Chang, Gee-Chen
    Tsai, Chen-Liang
    Yang, James C. -H.
    Chen, Yuh-Min
    Smit, Egbert F.
    van der Wekken, Anthonie J.
    Kato, Terufumi
    Juraeva, Dilafruz
    Stroh, Christopher
    Bruns, Rolf
    Straub, Josef
    Johne, Andreas
    Scheele, Juergen
    Heymach, John V.
    Le, Xiuning
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (10) : 931 - 943
  • [52] Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14-Mutant NSCLC
    Recondo, Gonzalo
    Bahcall, Magda
    Spurr, Liam F.
    Che, Jianwei
    Ricciuti, Biagio
    Leonardi, Giulia C.
    Lo, Ying-Chun
    Li, Yvonne Y.
    Lamberti, Giuseppe
    Nguyen, Tom
    Milan, Marina S. D.
    Venkatraman, Deepti
    Umeton, Renato
    Paweletz, Cloud P.
    Albayrak, Adem
    Cherniack, Andrew D.
    Price, Kristin S.
    Fairclough, Stephen R.
    Nishino, Mizuki
    Sholl, Lynette M.
    Oxnard, Geoffrey R.
    Janne, Pasi A.
    Awad, Mark M.
    [J]. CLINICAL CANCER RESEARCH, 2020, 26 (11) : 2615 - 2625
  • [53] Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNA
    Remon, J.
    Caramella, C.
    Jovelet, C.
    Lacroix, L.
    Lawson, A.
    Smalley, S.
    Howarth, K.
    Gale, D.
    Green, E.
    Plagnol, V.
    Rosenfeld, N.
    Planchard, D.
    Bluthgen, M. V.
    Gazzah, A.
    Pannet, C.
    Nicotra, C.
    Auclin, E.
    Soria, J. C.
    Besse, B.
    [J]. ANNALS OF ONCOLOGY, 2017, 28 (04) : 784 - 790
  • [54] Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC
    Rolfo, Christian
    Mack, Philip C.
    Scagliotti, Giorgio V.
    Baas, Paul
    Barlesi, Fabrice
    Bivona, Trever G.
    Herbst, Roy S.
    Mok, Tony S.
    Peled, Nir
    Pirker, Robert
    Raez, Luis E.
    Reck, Martin
    Riess, Jonathan W.
    Sequist, Lecia V.
    Shepherd, Frances A.
    Sholl, Lynette M.
    Tan, Daniel S. W.
    Wakelee, Heather A.
    Wistuba, Ignacio I.
    Wynes, Murry W.
    Carbone, David P.
    Hirsch, Fred R.
    Gandara, David R.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (09) : 1248 - 1268
  • [55] Utility of Genomic Assessment of Blood-Derived Circulating Tumor DNA (ctDNA) in Patients with Advanced Lung Adenocarcinoma
    Schwaederle, Maria C.
    Patel, Sandip P.
    Husain, Hatim
    Ikeda, Megumi
    Lanman, Richard B.
    Banks, Kimberly C.
    Talasaz, AmirAli
    Bazhenova, Lyudmila
    Kurzrock, Razelle
    [J]. CLINICAL CANCER RESEARCH, 2017, 23 (17) : 5101 - 5111
  • [56] Cell-free nucleic acids as biomarkers in cancer patients
    Schwarzenbach, Heidi
    Hoon, Dave S. B.
    Pantel, Klaus
    [J]. NATURE REVIEWS CANCER, 2011, 11 (06) : 426 - 437
  • [57] Comparative evaluation of cell-free tumor DNA in blood and disseminated tumor cells in bone marrow of patients with primary breast cancer
    Schwarzenbach, Heidi
    Pantel, Klaus
    Kemper, Birthe
    Beeger, Cord
    Otterbach, Friedrich
    Kimmig, Rainer
    Kasimir-Bauer, Sabine
    [J]. BREAST CANCER RESEARCH, 2009, 11 (05):
  • [58] Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches
    Shea, Meghan
    Costa, Daniel B.
    Rangachari, Deepa
    [J]. THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2016, 10 (02) : 113 - 129
  • [59] The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee
    Sholl, Lynette
    Hirsch, Fred R.
    Hwang, David
    Botling, Johan
    Lopez-Rios, Fernando
    Bubendorf, Lukas
    Mino-Kenudson, Mari
    Roden, Anja C.
    Beasley, Mary Beth
    Borczuk, Alain
    Brambilla, Elisabeth
    Chen, Gang
    Chou, Teh-Ying
    Chung, Jin-Haeng
    Cooper, Wendy A.
    Dacic, Sanja
    Lantuejoul, Sylvie
    Jain, Deepali
    Lin, Dongmei
    Minami, Yuko
    Moreira, Andre
    Nicholson, Andrew G.
    Noguchi, Masayuki
    Papotti, Mauro
    Pelosi, Giuseppe
    Poleri, Claudia
    Rekhtman, Natasha
    Tsao, Ming-Sound
    Thunnissen, Erik
    Travis, William
    Yatabe, Yasushi
    Yoshida, Akihiko
    Daigneault, Jillian B.
    Zehir, Ahmet
    Peters, Solange
    Wistuba, Ignacio I.
    Kerr, Keith M.
    Longshore, John W.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (09) : 1409 - 1424
  • [60] RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies
    Solomon, Benjamin J.
    Tan, Lavinia
    Lin, Jessica J.
    Wong, Stephen Q.
    Hollizeck, Sebastian
    Ebata, Kevin
    Tuch, Brian B.
    Yoda, Satoshi
    Gainor, Justin F.
    Sequist, Lecia V.
    Oxnard, Geoffrey R.
    Gautschi, Oliver
    Drilon, Alexander
    Subbiah, Vivek
    Khoo, Christine
    Zhu, Edward Y.
    Nguyen, Michele
    Henry, Dahlia
    Condroski, Kevin R.
    Kolakowski, Gabrielle R.
    Gomez, Eliana
    Ballard, Joshua
    Metcalf, Andrew T.
    Blake, James F.
    Dawson, Sarah-Jane
    Blosser, Wayne
    Stancato, Louis F.
    Brandhuber, Barbara J.
    Andrews, Steve
    Robinson, Bruce G.
    Rothenberg, S. Michael
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (04) : 541 - 549
12345678